Radionuclide Therapy of HER2-Positive Microxenografts Using a $^{177}\text{Lu}$-Labeled HER2-Specific Affibody Molecule

Vladimir Tolmachev,1,2,3 Anna Orlova,1,2 Rikard Pehrson,1,2 Joakim Galli,1 Barbro Baastrup,1 Karl Andersson,1 Mattias Sandström,3 Daniel Rosik,1 Jörgen Carlsson,1 Hans Lundqvist,2 Anders Wennborg,1 and Fredrik Y. Nilsson1,2

1Affibody AB, Bromma, Sweden; 2Division of Biomedical Radiation Sciences, Uppsala University; and 3Department of Hospital Physics, Uppsala University Hospital, Uppsala, Sweden

Abstract

A radiolabeled anti-HER2 Affibody molecule ($Z_{HER2:342}$) targets HER2-expressing xenografts with high selectivity and gives good imaging contrast. However, the small size ($\sim 7$ kDa) results in rapid glomerular filtration and high renal accumulation of radiometals, thus excluding targeted therapy. Here, we report that reversible binding to albumin efficiently reduces the renal excretion and uptake, enabling radiometal-based nuclide therapy. The dimeric Affibody molecule ($Z_{HER2:342}$) was fused with an albumin-binding domain (ABD) conjugated with the isothiocyanate derivative of CHX-AEC-DTPA and labeled with the low-energy $\beta$-emitter $^{177}\text{Lu}$. The obtained conjugate [CHX-AEC-DTPA-ABD($Z_{HER2:342}$)] had a dissociation constant of 18 pmol/L to HER2 and 8.2 and 31 nmol/L for human and murine albumin, respectively. The radiolabeled conjugate displayed specific binding to HER2-expressing cells and good cellular retention in vitro. In vivo, fusion with ABD enabled a 25-fold reduction of renal uptake in comparison with the nonfused dimer molecule ($Z_{HER2:342}$). Furthermore, the biodistribution showed high and specific uptake of the conjugate in HER2-expressing tumors. Treatment of SKOV-3 microxenografts (high HER2 expression) with 17 or 22 MBq $^{177}\text{Lu}$-CHX-AEC-DTPA-ABD($Z_{HER2:342}$) completely prevented formation of tumors, in contrast to mice given PBS or 22 MBq of a radiolabeled non-HER2-binding Affibody molecule. In LS174T xenografts (low HER2 expression), this treatment resulted in a small but significant increase of the survival time. Thus, fusion with ABD improved the in vivo biodistribution, and the results highlight $^{177}\text{Lu}$-CHX-AEC-DTPA-ABD($Z_{HER2:342}$) as a candidate for treatment of disseminated tumors with a high level of HER2 expression. [Cancer Res 2007;67(6):2773–82]

Introduction

Despite impressive progress in the therapy of localized cancer, the possibility to control disseminated disease is limited. Chemotherapy can be efficient, but the lack of specificity often causes an indiscriminate toxicity. A possible way to reduce the toxicity is to selectively accumulate cytotoxic substances in malignant tumors by targeting molecular structures, which are aberrantly expressed by the cancer cells. The use of radionuclides as a cytotoxic payload can be of advantage because the phenomenon of multidrug resistance is unknown for radionuclides and because of the so-called cross-fire effect (i.e., irradiation of cancer cell by nuclides delivered to their malignant neighbors; ref. 1). The radionuclide-labeled anti-lymphoma antibodies Zevalin ($^{90}\text{Y}$) and Bexxar ($^{131}\text{I}$) showed clear improvement in response rates in comparison with nonradiolabeled counterparts (2, 3), but targeted radionuclide therapy of solid tumors has thus far not achieved a decisive breakthrough. This could partially be explained by the fact that solid tumors are generally more radioresistant than lymphomas. However, the major problem is that existing methods cannot provide the required level of radioactivity accumulation in tumors without delivering unacceptably high doses to critical organs, especially to bone marrow (4). The slow blood clearance and the slow extravasation and tumor penetration are limiting factors of intact immunoglobulins, which have mainly been used as targeting agents in radionuclide therapy. To improve tumor-to-nontumor dose ratios by improving extravasation and interstitial diffusion, smaller antibody fragments (5, 6) and peptide ligands to receptors that are overexpressed in tumors (7) have been considered as targeting agents for radionuclide therapy.

We have recently reported on tumor targeting of a HER2-specific molecule derived from a new class of affinity proteins called Affibody molecules (8, 9). Affibody molecules are small, very stable, 58-amino-acid residue protein domains derived from one of the IgG-binding domains of staphylococcal protein A. The three-helix bundle structure has been used as scaffold for construction of combinatorial libraries, from which Affibody molecule variants that target desired molecules can be selected (10, 11).

Overexpression of the oncogene HER2 (human epidermal growth factor receptor 2, c-erbB2, neu) is considered a part of the malignant phenotype and has been detected in a number of malignant tumors, such as carcinomas of breast, ovary, and urinary bladder (12–14). A monoclonal antibody directed against HER2 (trastuzumab) is a registered therapeutic for breast cancer (15), and a number of small-molecule kinase inhibitors (16) and vaccine strategies (17) are in clinical development. HER2 is also considered as a promising target for radionuclide therapy of, for example, breast cancer (18), and both HER2-recognizing antibodies and their fragments have been evaluated in this context (19–23).

We considered that the small size ($\sim 7$ kDa) and high affinity ($K_D = 22$ pmol/L) of the anti-HER2 Affibody molecule would enable quick extravasation and tumor penetration as well as provide strong binding to the tumor-associated antigen. Indeed,
high tumor-to-nontumor ratios were obtained for the anti-HER2 Affibody molecule labeled with isotopes of iodine (9, 24), bromine (25), technetium (26), and indium (27). Although all labeling technologies enabled high-contrast gamma camera imaging of HER-2 expression in tumor xenografts, radiometal accumulation in kidneys was high. This may be acceptable for imaging purposes but could be associated with toxicity problems in radiotherapeutic applications.

We hypothesized that it should be possible to reduce the kidney accumulation by associating the radiolabeled Affibody molecule to serum albumin. Albumin (molecular mass, 67 kDa) is present at 50 mg/mL (600 µmol/L) in human and murine plasma (28) and has a long half-life. The pharmacokinetics of small proteins and peptides have been modified by making fusions to albumin (29–31). A technically simpler and possibly more attractive approach is based on reversible noncovalent binding to the patient’s own serum albumin (32, 33). We chose to work with an albumin-binding domain (ABD), a monovalent variant of an albumin-binding motif of streptococcal protein G (32). Fusing the Affibody molecule to ABD permits binding of the fusion protein to the patient’s own serum albumin following administration, thereby prolonging plasma half-life and reducing uptake in kidneys. As there are several ABD variants with different affinities for albumin available (34), one could foresee modifications of pharmacokinetics by manipulating the affinity of ABD to albumin. Serum albumin extravasates, and the major portion is interstitially located. Furthermore, the combined molecular weight of albumin and the Affibody construct used in this study [ABD-(ZHER2:342)2] is less than the molecular weight of IgG or its (Fab)2 fragment. Together with an expected free, non–albumin-bound fraction of ABD-(ZHER2:342)2, with size 20 kDa, this could provide for a more efficient extravasation and diffusion in the tumor interstitium.

The goal of this study was to evaluate if fusing the anti-HER2 Affibody molecule ZHER2:342 to the ABD could improve the pharmacokinetics and enable radionuclide therapy of very small HER2-expressing tumors. As the most appropriate application for targeted radionuclide therapy of solid tumors is minimal residual disease (4, 35), radionuclides with low β energy should be most suitable as labels. Among commercially available nuclides, 177Lu (T1/2 = 7.7 days, <Eβ> = 133 keV) and 131I (T1/2 = 8.02 days, <Eβ> = 182 keV) can be considered as the most suitable for this application, both in terms of emitted radiation and half-life.

Materials and Methods

Production of (ZHER2:342)2 and ABD-(ZHER2:342)2. A DNA fragment encoding ZHER2:342 was PCR-amplified and subcloned in two pET (Novagen, Madison, WI) derived expression vectors (pAY492 and pAY540). The molecule was subliced in dimeric form by using the restriction enzyme AccI. The pAY540 vector contains the gene for ABD located upstream of the AccI cloning site. The resulting vector pAY773 encodes the bivalent Affibody molecule (ZHER2:342)2, and pAY770 encodes (ZHER2:342)2 in fusion with a NHE-terminal ABD

The resulting pAY770 [ABD-(ZHER2:342)2] and pAY773 [(ZHER2:342)2] were transformed to chemocompetent Escherichia coli strain BL21(DE3) (Novagen). ABD-(ZHER2:342)2 was expressed in shaker flasks; the cell pellet was disrupted through sonication; and the protein was affinity purified using in-house coupled human serum albumin on CNBr-activated Sepharose 4FF (Amersham Biosciences AB, Uppsala, Sweden) and reverse-phase column, RESOURCE RPC 3 mL (Amersham Biosciences).

Remanining endotoxins were removed using detoxigel columns (Pierce, Rockford, IL), (ZHER2:342)2 was fermented, and the cells were disintegrated by sonication on ice and centrifuged. The supernatant was purified on a cation exchange column SP Sepharose Fast Flow (Pharmacia Biotech, Uppsala, Sweden) and a reverse-phase column RESOURCE RPC 3 mL (Amersham Biosciences). Remaining endotoxins were removed using detoxigel columns (Pierce).

Conjugation and labeling chemistry. [111In]In-ABD-(ZHER2:342)2 was labeled using p-iodobenzoate linker according to the procedure described by Orlova et al. (9).

Conjugation of the isothiocyanate derivative of CHX-A-DTPA to Affibody molecules, both specific ABD-(ZHER2:342)2 and nonspecific ABD-(ZHER2:342)2 was done at elevated temperature in alkaline aqueous solution, according to a method previously used (27), using a chelator-to-protein molar ratio of 1:1. Briefly, 333 µL ABD-(ZHER2:342)2 (400 µg) was mixed with 16 µL of freshly prepared solution (1 mg/mL) of isothiocyanate-CHX-A-DTPA (Macrocyclics, Dallas, TX) in 0.07 mol/L sodium borate buffer (pH 9.2). The total volume was adjusted to 500 µL with 0.07 mol/L borate buffer, after which the mixture was vortexed for about 30 s and then incubated overnight at 37°C. After incubation, the reaction mixture was purified on a NAP-5 size exclusion column pre-equilibrated with 1 mol/L ammonium acetate buffer (pH 5.5) containing 5 g/L ascorbic acid. The eluate was vortexed and stored at −20°C before labeling. Nonspecific ABD-fused ABD-(ZHER2:342)2 Affibody molecule and non-ABD-fused (ZHER2:342)2 was conjugated with chelator using the same protocol.

To evaluate the efficiency of isothiocyanate-CHX-A-DTPA coupling to (ZHER2:342)2, two samples were analyzed by high-performance liquid chromatography and online mass spectrometry (HPLC-MS) using an Agilent 1100 HPLC/MSD. The mass spectrometer was equipped with electrospray ionization and single quadrupole. A Zorbax 300SB-C18 (4.6 × 150, 3.5 µm; Agilent, Santa Clara, CA) RPC column eluted with water/acetonitrile gradient with 0.1% trifluoroacetic acid was used.

For labeling, a predetermined amount of conjugate in 1 mol/L ammonium acetate buffer (pH 5.5) was de-frozen and mixed with a predetermined amount of 177Lu and incubated at room temperature for 30 to 60 min. A 2-fold molar excess of Affibody molecule over lutetium was used.

For routine quality control of the labeling, ITLC SG (silica gel impregnated glass fiber sheets for instant TLC, Gelman Sciences, Inc., East Hills, NY) eluted with 0.2 mol/L citric acid was used. In this system, radiolabeled Affibody molecules remain at origin, free lutetium migrates with the front of solvent, and 177Lu-CHX-A-DTPA complex has a Rf of 0.4. Distribution of radioactivity along the instant TLC strips was measured on a Cyclone Storage Phosphor System and analyzed using the OptiQuant image analysis software.

Affinity was measured using Biacore 3000 (Biacore AB, Uppsala, Sweden) with Sensor Chip CMS. HER-2 was immobilized using amino chemistry according to the manufacturer’s instructions. To obtain monomeric affinity, surface density of ECD-HER2 was kept low to exclude avid interaction of the conjugate with two receptors simultaneously. Conjugate was injected for 600 s at five concentrations ranging from 15 pmol/L to 6.4 nmol/L. Results were evaluated with BIAlEvaluation 4.0 (Biacore) using a 1:1 interaction model.

Cell binding and retention studies. The binding specificity of the obtained conjugates was tested on HER2-expressing SKOV-3 ovarian cancer cells according to method described earlier (26). For HER2 saturation, a 1,000-fold excess of nonlabeled Affibody molecule or pertuzumab was used. To evaluate how residualizing properties of label affect the retention, a cellular retention of radioactivity after interrupted incubation with 125I-ABD-(ZHER2:342)2 and 177Lu-CHX-A-DTPA-ABD-(ZHER2:342)2 was studied according to the method described by Orlova et al. (9). To assess the chemical form of radioactivity in the medium after 72 h of incubation, medium was passed through size-exclusion NAP-5 columns (0.5 mL from each sample), and radioactivity of fractions was measured.

Comparative biodistribution of (ZHER2:342)2 with and without ABD in normal mice. All animal studies were approved by the local Ethics
Committee. To evaluate influence of ABD on biodistribution, $^{177}$Lu-CHX-A"-DTPA-(ZHER2/342)2 and $^{177}$Lu-CHX-A"-DTPA-ABD-(ZHER2/342)2 were given s.c. to female NMRI mice (12 weeks; Taconic Europe A/S, Ry, Denmark). At 1 [only (ZHER2/342)2], 4, 8, 24, 48, and 72, and 168 h after injection, animals were injected with a lethal dose of Ketalar/Bompun and dissected (n = 4 for each time point). Blood, lung, liver, spleen, kidneys, salivary glands, skin, and bone were collected for radioactive measurement. Uptake was calculated and expressed as percent injected activity per gram (% IA/g).

**Tumor uptake and biodistribution of $^{177}$Lu in SKOV-3 xenograft-bearing nude mice after s.c. injection of $^{177}$Lu-CHX-A"-DTPA-ABD-(ZHER2/342)2.** Female mice (BALB/c nu/nu; 10–12 weeks old at arrival; Taconic) were injected with $-10^7$ SKOV-3 cells s.c. in the hind leg 4 weeks before the experiment. Forty mice with SKOV-3 tumor xenografts were randomized into 10 groups (n = 4). Eight groups of mice were injected s.c. with $1 \mu$g $^{177}$Lu-CHX-A"-DTPA-ABD-(ZHER2/342)2 with activity of 110 kBq in 100 µL PBS and killed 1, 4, 12, 24, 48, 72, and 168 h after injection. For specificity control, the ninth group was pretreated with nonlabeled ABD-(ZHER2/342)2 (335 µg, 0.5 mL PBS) 45 min before injection of $^{177}$Lu-CHX-A"-DTPA-ABD-(ZHER2/342)2 and killed 24 h after injection. To evaluate the level of nonspecific accumulation in tumors, the 10th group was injected s.c. with non–HER2-specific Affibody molecule $^{177}$Lu-DTPA-CHX-A"-ABD-(Zabeta)2 (1 µg, 110 kBq, 100 µL PBS) and sacrificed 48 h after injection. Blood, lung, liver, spleen, kidneys, salivary glands, skin, and bone were collected for radioactive measurement subsequently expressed as % IA/g. Typical weight of xenografts excised during first 24 h of the study was $-100$ mg. At the end of the study, xenograft weight increased to about 250 mg due to tumor growth.

**Dosimetry calculations.** The organ uptake values from the biodistribution study, noncorrected for physical half-life, were time integrated to obtain the residence time per gram tissue for dosimetry calculations. Integration between time 0 and 332 h was made by the trapezoid method. The two last time points were fitted to a single exponential function, which extrapolation area was less than a few percent in all organs except the liver. Integration between time 0 and 332 h was made by the trapezoid method.

**Results**

Production of (ZHER2/342)2 and ABD-(ZHER2/342)2

The purified proteins were identified and characterized by LC/MS and SDS-PAGE. In both analyses, no contaminants could be detected, and the purity of the proteins was determined from the LC/MS to be $>98\%$. The molecular masses were in agreement with the theoretical values. The final concentration of ABD-(ZHER2/342)2 was 1.58 mg/mL and for (ZHER2/342)2 1.14 mg/mL.

Conjugation and Labeling Chemistry

LS/MS showed that on average, 0.91 chelator was coupled per molecule of ABD-(ZHER2/342)2. We did not further increase the number of chelator per protein due to the risk of over-modification. According to surface plasmon resonance measurement, a chelator-coupled Affibody molecule retained high affinity both to albumin ($K_d$ of 31 and 8.2 nmol/L to murine and human albumin, respectively) and to the extracellular domain of HER2 (18 pmol/L). Labeling of CHX-A"-DTPA-ABD-(ZHER2/342)2 was quick and efficient, providing yield of 88.6 ± 2.0% after 15 min and 96.8 ± 0.6% after 30 min (n = 6), with very little batch-to-batch variation.

Cell Binding and Retention Studies

In agreement with the surface plasmon resonance data, radio-labeled conjugate retained capacity to bind to living HER2-expressing SKOV-3 cells. Presaturation of receptor with an excess of nonlabeled ABD-(ZHER2/342)2 caused almost complete blocking of...
binding (data not shown). An attempt to add a blocking amount of pertuzumab did not reduce binding at all, which indicates that these two targeting proteins bind to different epitopes.

Cellular retention experiments showed much better retention of $^{177}$Lu label in comparison with radioiodine one (Fig. 1). This is a strong indication of internalization of the $\text{ABD-}^{(ZHER2:342)2}$–based conjugates. Good retention, typical for radiometals, resulted in that only 5% to 10% of lutetium in the medium was bound to high-molecular-weight compounds. This indicates that exocytosis of degraded Affibody molecules is the main route of decrease of cell-associate radioactivity.

**Comparative Biodistribution of $^{(ZHER2:342)2}$ with and without ABD in Normal Mice**

Results of the comparison of $^{(ZHER2:342)2}$ with or without ABD are presented in Table 1. The residence of $^{(ZHER2:342)2}$ in the blood circulation was prolonged with an increase of the half-life from 0.64 ± 0.2 to 35.8 ± 0.0 h, and radioactivity uptake in kidney was reduced 25-fold in comparison with the peak value for $^{177}$Lu-CHX-A$^\text{D}$-DTPA-$(^{ZHER2:342)2}$. Low uptake in bone indicated high stability of chelate and confirmed that the chelator was suitable for therapy. The radioactivity concentration in organs and tissues after injection of $^{177}$Lu-CHX-A$^\text{D}$-DTPA-$(^{ZHER2:342)2}$ generally followed its kinetics in blood.

**Tumor Uptake and Biodistribution of $^{177}$Lu in SKOV-3 Xenograft-Bearing Nude Mice after Subcutaneous Injection of $^{177}$Lu-CHX-A$^\text{D}$-DTPA-$(^{ZHER2:342)2}$**

Biodistribution and dosimetric data are presented in Table 2. The biodistribution showed high uptake in the tumors after about 24 h after injection. Then, tumor radioactivity concentration exceeded that in blood and kidneys. Concentration in blood and kidneys (highest among healthy tissue) peaked at 12 and 24 h after injection, respectively. Skin uptake was also high, in agreement with abundance of albumin due to relatively large fractional interstitial volume (37). Bone uptake was low, indicating that free $^{177}$Lu was neither released when $^{177}$Lu-CHX-A$^\text{D}$-DTPA-$(^{ZHER2:342)2}$ was in circulation nor after its degradation in tumor and excretory organs. Radioactivity in normal organs decreased with time, mainly following blood kinetics. Exceptions were liver and spleen, which is probably a sign of internalization of the conjugate.

Importantly, specificity of tumor uptake was shown in two independent experiments (Fig. 2). First, preinjecting large molar excess of nonlabeled ABD-$(^{ZHER2:342)2}$ decreased tumor uptake 24 h after injection from 19 ± 7 to 6.7 ± 0.3% IA/g ($P < 0.05$), proving saturability of tumor uptake and a receptor-mediated mechanism. There were no statistically significant differences in uptake for other organs with or without pretreatment with nonlabeled ABD-$(^{ZHER2:342)2}$.

In the second experiment, a nonspecific Affibody dimer fused to ABD was injected. A comparison showed significantly lower levels ($P < 0.0005$) of radioactivity at 48 h not only in the tumor but also in blood. However, the reduction of blood level was only 2-fold, whereas tumor accumulation was 9.6-fold lower. This indicated that accumulation of $^{177}$Lu-CHX-A$^\text{D}$-DTPA-$(^{ZHER2:342)2}$

---

**Table 1. Comparative biodistribution of $^{177}$Lu-CHX-A$^\text{D}$-DTPA-$(^{ZHER2:342)2}$ and $^{177}$Lu-CHX-A$^\text{D}$-DTPA-$(^{ZHER2:342)2}$ in NMRI mice**

<table>
<thead>
<tr>
<th></th>
<th>1 h</th>
<th>4 h</th>
<th>8 h</th>
<th>24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$(^{ZHER2:342)2}$</td>
<td>$(^{ZHER2:342)2}$</td>
<td>ABD-$(^{ZHER2:342)2}$</td>
<td>ABD-$(^{ZHER2:342)2}$</td>
</tr>
<tr>
<td>Blood</td>
<td>1.2 ± 0.3</td>
<td>0.059 ± 0.004</td>
<td>5 ± 1</td>
<td>0.027 ± 0.001</td>
</tr>
<tr>
<td>Lung</td>
<td>1.0 ± 0.2</td>
<td>0.26 ± 0.03</td>
<td>1.5 ± 0.4</td>
<td>0.24 ± 0.05</td>
</tr>
<tr>
<td>Liver</td>
<td>1.2 ± 0.2</td>
<td>1.5 ± 0.4</td>
<td>1.0 ± 0.3</td>
<td>1.5 ± 0.2</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.7 ± 0.2</td>
<td>0.5 ± 0.1</td>
<td>0.6 ± 0.3</td>
<td>0.41 ± 0.08</td>
</tr>
<tr>
<td>Kidney</td>
<td>109 ± 7</td>
<td>149 ± 38</td>
<td>58 ± 0.6</td>
<td>155 ± 20</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.6 ± 0.1</td>
<td>0.25 ± 0.06</td>
<td>0.7 ± 0.1</td>
<td>0.24 ± 0.05</td>
</tr>
<tr>
<td>Skin</td>
<td>3 ± 3</td>
<td>1 ± 1</td>
<td>1 ± 1</td>
<td>0.58 ± 0.07</td>
</tr>
<tr>
<td>Bone</td>
<td>0.5 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.2</td>
<td>0.24 ± 0.05</td>
</tr>
</tbody>
</table>

NOTE: Each data point presents an average from four animals ± SD and is expressed as the percentage of injected radioactivity per gram organ or tissue.

Abbreviation: NM, not measurable.
in tumor depends on its interaction with HER2-receptors and not on unspecific trapping of proteins in tumor interstitium as a consequence of higher fractional interstitial volume of tumor tissue. The lower blood concentration of nonspecific Affibody may suggest that some part of the radiolabeled \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(ZHER2:342)\(_2\) dissociated continuously from the receptors, was drained from the tumors, and then re-entered the blood circulation, whereas such a depot did not exist for the nonspecific Affibody \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(Zabeta)\(_2\).

**Gamma-Camera Imaging**

Gamma-camera imaging (Fig. 3) confirmed good tumor targeting properties of \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(ZHER2:342)\(_2\). It was seen that already 52 h after injection, tumor xenografts were the only sites of prominent accumulation of radioactivity. Elevated (in comparison with rest of the animal) radioactivity accumulation was also seen in the abdominal area. However, there was no clear visualization of kidneys, which has been characteristic for previously obtained gamma-camera images using radiometal-labeled Affibody molecules that were not fused with ABD.

### Experimental Radionuclide Therapy of Microxenografts

**SKOV-3 (high HER2 expression) xenografts.** For vehicle-treated animals (n = 10), tumors appeared in seven animals 36 to 62 days (median, 43 days) after injection. Mice with tumors were euthanized 67 to 104 days (median, 67 days) after administration due to tumor growth.

Among mice given 21.4 MBq (n = 10) of nonspecific \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(Zabeta)\(_2\), tumors appeared in six animals 18 to 85 days (median, 43 days) after administration. Compared with vehicle-treated mice, there was no statistical significant difference.

Among mice given 17.4 (n = 10) and 21.6 MBq (n = 22) \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(ZHER2:342)\(_2\), tumors could not be detected throughout the study period. Thus, tumor-free survival was significantly different (17.4 MBq, P < 0.05; 21.6 MBq, P < 0.001) compared with mice treated with 21.4 MBq \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(Zabeta)\(_2\). Except for two animals that had to be euthanized days 1 and 18 after drug administration due to loss of weight, all animals survived tumor-free up to study termination (Fig. 4).

### Table 1. Comparative biodistribution of \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-(ZHER2:342)\(_2\) and \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(ZHER2:342)\(_2\) in NMRI mice (Cont’d)

<table>
<thead>
<tr>
<th></th>
<th>(^{177})Lu-CHX-A(^{-})DTPA-(ZHER2:342)(_2)</th>
<th>(^{177})Lu-CHX-A(^{-})DTPA-ABD-(ZHER2:342)(_2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>48 h</td>
<td>72 h</td>
</tr>
<tr>
<td></td>
<td>(^{177})Lu-CHX-A(^{-})DTPA-(ZHER2:342)(_2)</td>
<td>(^{177})Lu-CHX-A(^{-})DTPA-ABD-(ZHER2:342)(_2)</td>
</tr>
<tr>
<td></td>
<td>0.006 ± 0.001</td>
<td>0.007 ± 0.002</td>
</tr>
<tr>
<td></td>
<td>0.10 ± 0.04</td>
<td>0.06 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.8 ± 0.1</td>
<td>0.6 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>0.3 ± 0.1</td>
<td>0.17 ± 0.05</td>
</tr>
<tr>
<td></td>
<td>54 ± 7</td>
<td>34 ± 11</td>
</tr>
<tr>
<td></td>
<td>0.11 ± 0.04</td>
<td>0.09 ± 0.01</td>
</tr>
<tr>
<td></td>
<td>0.5 ± 0.2</td>
<td>0.6 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>0.1 ± 0.1</td>
<td>0.13 ± 0.08</td>
</tr>
</tbody>
</table>

### Table 2. Biodistribution and dosimetry of \(^{177}\)Lu-CHX-A\(^{-}\)DTPA-ABD-(ZHER2:342)\(_2\) in BALB/c nu/nu mice bearing HER2-expressing SKOV-3 xenografts

<table>
<thead>
<tr>
<th></th>
<th>% IA/g</th>
<th>Gy/MBq</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>0.9 ± 0.3</td>
<td>0.43 ± 0.07</td>
</tr>
<tr>
<td>Tumor</td>
<td>1.9 ± 0.4</td>
<td>0.007 ± 0.004</td>
</tr>
<tr>
<td>Heart</td>
<td>1.5 ± 0.3</td>
<td>0.51 ± 0.3</td>
</tr>
<tr>
<td>Lung</td>
<td>2.4 ± 0.4</td>
<td>0.25 ± 0.02</td>
</tr>
<tr>
<td>Liver</td>
<td>3.9 ± 0.3</td>
<td>0.25 ± 0.02</td>
</tr>
<tr>
<td>Spleen</td>
<td>3.0 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Pancreas</td>
<td>3.0 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Stomach</td>
<td>1.6 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Intestine</td>
<td>1.5 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Kidney</td>
<td>1.5 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>1.5 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Skin</td>
<td>1.5 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Muscle</td>
<td>1.3 ± 0.3</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Bone</td>
<td>1.4 ± 0.2</td>
<td>0.53 ± 0.04</td>
</tr>
<tr>
<td>Brain</td>
<td>0.23 ± 0.01</td>
<td>0.016 ± 0.004</td>
</tr>
</tbody>
</table>


Downloaded from cancerres.aacrjournals.org on April 13, 2017. © 2007 American Association for Cancer Research.
Animal weight was not different between the groups on the day of administration. Following drug administration, body weight was not significantly different among the groups, up to 78 days after administration, except for mice given 29.6 MBq. Thereafter, body weight in vehicle-treated mice was significantly lower compared with mice given 17.4 to 21.6 MBq 177Lu-CHX-A00-DTPA-ABD-(ZHER2:342)2. The decrease of body weight in this group was due to tumor development.

Mice given 29.6 MBq (n = 12) had to be sacrificed 8 to 18 days after drug administration due to illness and decline in body weight. In blood analyzed from three of these mice, no leukocytes were observed. In vehicle-treated mice, blood leukocyte counts were 3.0 to 4.2 × 10⁹ cells per mL (n = 4), close to that found in normal mice. This indicates that myelotoxicity was dose limiting.

Serum creatinine concentration in treated mice sacrificed at the study end (21.6 MBq, n = 9, 26–33 μmol/L) or 6 months after drug administration (17.5 MBq, n = 4, 17–27 μmol/L; 21.6 MBq, n = 2, 25–31 μmol/L) was not significantly different compared with vehicle-treated mice (n = 3, 23–24 μmol/L), except for one mouse given 17.4 MBq (94 μmol/L). Histopathology examinations of kidneys in mice given 17.4 MBq and sacrificed 3 weeks later revealed no pathologic changes.

LS174T (low HER2 expression) xenografts. The therapy study was also done in the LS174T model, which served as a model for tumors with low HER2 expression. Mice that were treated with 22.2 MBq of 177Lu-CHX-A00-DTPA-ABD-(ZHER2:342)2 had a statistically significant prolonged survival compared with mice treated with 22.3 MBq of the non–HER2-specific control Affibody molecule 177Lu-CHX-A00-DTPA-ABD-(Zabetas)2 (P = 0.006) or vehicle (P = 0.001; Fig. 4B). Although the initial reduction in tumor growth was apparent for the treated group, tumor formation was not prevented in this study. The main cause of animal euthanasia in the treatment group was tumor ulceration rather than overgrowth. No increase in serum creatinine concentration was observed (n = 6), and body weight was not different among the groups.

Discussion

Design of tumor targeting radiopharmaceuticals is a complex problem, which requires a careful consideration of a number of factors, such as nature of the tumor-associated target, including cellular processing of target-targeting agent complex, the physical properties of the radionuclide, labeling chemistry, and biodistribution properties of the targeting agents. This study is concentrated mainly on the biodistribution aspect. Radioimmunotherapy studies have mainly used IgG as a targeting vector (38). Long circulation time provides high tumor accumulation of slowly extravasating bulky immunoglobulins but, at the same time, causes unacceptably high doses to bone marrow. This can be avoided by increasing the tumor to blood ratio by improving

Figure 2. Specificity of 177Lu-CHX-A00-DTPA-ABD-(ZHER2:342)2 uptake in HER2-expressing xenografts. A, one group of animals was preinjected with 335 μg of nonlabeled ABD-(ZHER2:342)2 to saturate HER2 receptors 45 min before injection of radiolabeled conjugate. All animals were injected with 20 μg 177Lu-CHX-A00-DTPA-ABD-(ZHER2:342)2 and dissected 24 h after injection. Significant difference (P < 0.05) between blocked and nonblocked groups was only observed in tumors. Columns, mean (n = 4); bars, SD. B, one group of animals was injected with 20 μg of nonspecific 177Lu-CHX-A00-DTPA-ABD-(Zabetas)2 Affibody molecule and dissected 48 h after injection. Significant difference (P < 0.05) between specific and nonspecific Affibody molecules were observed both in blood and tumors. Columns, mean (n = 4); bars, SD.
extravasation and tumor penetration, or reducing blood residence time, or combining both approaches. Several alternative methodologies aiming to minimize residence time of radioactivity in circulation and/or improving tumor localization are under evaluation, such as different ways of pre-targeting (39), extracorporeal filtration of radiolabeled antibodies (40), avidin chase of biotinylated antibodies (41), the engineering of smaller antibody-base constructs (5) or the use of peptide receptor ligands (7) with fast blood kinetics. We previously developed the ZHER2:342 Affibody molecule with very rapid (within 1 h) tumor localization and elimination, resulting in high tumor/nontumor ratios. However, radioactive dose to kidneys was unacceptably high for both nonresidualizing iodine (9) and residualizing indium (27) labels. ZHER2:342, being a small protein, is freely filtered through glomerular membranes and subsequently reabsorbed into kidney parenchyma. In this study, we aimed for a reduction in renal accumulation by noncovalent binding to albumin preventing glomerular filtration.

A monovalent and divalent form of ZHER2:342 were fused to ABD. We found that the monovalent form had a decrease in binding affinity to HER2, both in biosensor measurements (20-fold lower) and in experiments with living HER2-expressing cells (data not shown). A possible reason could be steric hindrance of ABD in binding of the ZHER2:342, as the on-rate but not the off-rate was affected. The use of high-affinity targeting agents for therapy is controversial. Adams et al. (23) have earlier observed that increase of affinity of scFv beyond \( K_d \) of 1 nmol/L may not increase quantitative retention of radioiodine label in tumors and can result in an nonhomogenous uptake, predominantly around blood vessels. However, modeling studies (42, 43) on targeting \( \beta \)-emitting nuclides, as in our case, suggest that the highest affinity provides the highest dose to the tumor. Our earlier results with non–ABD-fused anti-HER2 Affibody molecules showed increase of tumor localization with increase of affinity (9). For this reason, a high-affinity divalent form was selected.

In vitro analysis confirmed that both \(^{125}\text{I}-\text{PIB-ABD-(ZHER2:342)}_2\) and \(^{177}\text{Lu-CHX-A'°-DTPA-ABD-(ZHER2:342)}_2\) conjugates retained capacity to bind to HER2-expressing cells in vitro. However, cellular retention experiments showed appreciably better retention of the residualizing metal label \((^{177}\text{Lu})\) in comparison with the nonresidualizing halogen \((^{125}\text{I})\). Because poor intracellular retention reduces both the radioactivity accumulation in tumors and the specificity of targeting (43, 44), the \(^{177}\text{Lu}-\text{labeled conjugate was selected for further investigations. Interestingly, we have found that }^{177}\text{Lu-CHX-A'°-DTPA-ABD-(ZHER2:342)}_2\) binds to a different epitope than pertuzumab. Together with our earlier finding that \(Z_{\text{HER2:342}}\) does not compete with trastuzumab for binding (8), this opens an opportunity to combine treatments.

In vivo comparison with the non–ABD-fused \(^{177}\text{Lu-CHX-A'°-DTPA-(ZHER2:342)}_2\) clearly showed the altered biodistribution as a consequence of fusion with ABD. The effect was most apparent for the blood clearance rate and kidney uptake. Such an effect can only be explained by binding of \(^{177}\text{Lu-CHX-A'°-DTPA-ABD-(ZHER2:342)}_2\) to albumin.

The biodistribution study in xenograft-bearing mice showed the capacity of \(^{177}\text{Lu-CHX-A'°-DTPA-(ZHER2:342)}_2\) to accumulate in HER2 expressing tumors. Importantly, the tumor uptake was receptor specific, as shown in control experiments that included (a) partial saturation of receptors in vivo and (b) the use of an unspecified Affibody molecule dimer fused with ABD.

It would be interesting to compare \(^{177}\text{Lu-CHX-A'°-DTPA-ABD-(ZHER2:342)}_2\) with other HER2-targeting molecules, which have been described in the literature. A quantitative comparison is complicated because of the large variation in tumor models and mouse strains. However, some qualitative conclusions can be done. Although smaller antibody-fragment based conjugates provide good tumor-to-blood ratios, the use of radiometal-labeled Fab and (Fab')2, fragments of trastuzumab (45, 46), or anti-HER2 diabodies (47) and minibodies (22) caused much higher accumulation of radioactivity in kidneys than in tumors. In

![Figure 3](image-url)
A

Figure 4. A, tumor-free survival of BALB/c nu/nu mice with small, established s.c. SKOV-3 tumors versus time. Animals were treated with a single injection of 177Lu-CHX-A'-DTPA-ABD-(ZH342)_2 (17.4, 21.6, or 29.6 MBq). Animals in control groups were treated either with PBS or with 21.4 MBq of nonspecific 177Lu-CHX-A'-DTPA-ABD-(Zalpha)2. B, survival until euthanasia criteria of BALB/c nu/nu mice with s.c. LS174T tumors versus time. Animals were treated with a single injection of 177Lu-CHX-A'-DTPA-ABD-(ZH342)_2 (22.2 MBq). Animals in control groups were treated either with PBS or with 23.2 MBq of nonspecific 177Lu-CHX-A'-DTPA-ABD-(Zalpha)2.

In this study, a radioactivity dose sufficient to prevent formation of xenografts with high HER2 expression (up to 21.6 MBq) had no negative effect on the kidneys, assessed by renal histopathology and function (serum creatinine concentration). Our observation is consistent with the literature data. For example, Behr et al. have found in a comprehensive study on renal toxicity due to radiolabeled conjugates. However, the tumor formation was not prevented completely. The results of this study imply that careful patient selection is a prerequisite for targeting radionuclide therapy, because only patients with high target expression are expected to get a maximum benefit from such treatment.

Recently, experimental therapy of nonestablished SKOV-3 xenografts was done using a 177Lu-labeled anti-HER2 antibody pertuzumab (48). The same chelator (CHX-A'-DTPA) was used in that study, and the study protocol was similar to the protocol used in the present study. It was found that both the residence time in blood and tumor uptake were higher for the antibody, whereas kidney uptake was appreciably lower than that for 177Lu-CHX-A'-DTPA-ABD-(ZH342)_2. According to calculations based on biodistribution in mice bearing macroscopic xenografts, treatment with 7 MBq 177Lu-CHX-A'-DTPA-pertuzumab delivered approximately the same dose to blood as 21.6 MBq 177Lu-CHX-A'-DTPA-ABD-(ZH342)_2 in this study, but the dose on the tumor was somewhat higher: 50 Gy for the antibody versus 45 Gy for the Affibody molecule–based conjugate. In the case of 177Lu-CHX-A'-DTPA-pertuzumab, a significant increase of survival was achieved in the treatment groups, but in contrast to our current study, tumor formation was not prevented. One possible explanation could be different dose distribution pattern within the xenograft. The tumor cell clump had a diameter of 2 to 3 mm at the time of the treatment. Hypothesizing that pertuzumab due to its size has lower penetration efficiency than the ABD-(ZH342)_2 molecule, the antibody would stay more localized close to the rim of the tumor (especially if the tumor has not yet become well vascularized). In this case, a cross-fire of low-energy β-particles of 177Lu (mean range, 0.67 mm) would be insufficient to completely eradicate radioresistant hypoxic cells in the middle of the clamp. The smaller complex of 177Lu-CHX-A'-DTPA-(ZHER2)_2 with albumin and particularly the locally released free fraction of 177Lu-CHX-A'-DTPA-ABD-(ZH342)_2 might penetrate deeper into the tumor and thus provide a more efficient cross-fire effect.

To evaluate the influence of HER2 expression level on the therapy outcome (Fig. 4B), we selected LS174T as a model of a tumor with low HER2 expression (49). A lower therapeutic effect could be expected in this case, as there would be fewer receptors per cell that could be targeted by the radiolabeled conjugate. This experiment showed prolonged survival in the case of specific radiolabeled conjugate. However, the tumor formation was not prevented completely. The results of this study imply that careful patient selection is a prerequisite for targeting radionuclide therapy, because only patients with high target expression are expected to get a maximum benefit from such treatment.

In this study, a radioactivity dose sufficient to prevent formation of xenografts with high HER2 expression (up to 21.6 MBq) had no negative effect on the kidneys, assessed by renal histopathology and function (serum creatinine concentration). Our observation is consistent with the literature data. For example, Behr et al. have found in a comprehensive study on renal toxicity due to radionuclide therapy that at renal doses of 40 Gy and even 66 Gy, “no renal toxicity was observed” in a murine model (50). The authors found that acute renal toxicity, with acute nephritis-like picture, was observed at doses above 100 Gy the first weeks after treatment, whereas after more than 5 weeks, and lower doses (about 80 Gy), renal damages in mice resembled chronic radiation
nephris. The renal dose for mice treated with 22 MBq in our study was 30 Gy. For comparison, studies on treatment of SKOV-3 using C6.5 diabodies showed a high renal accumulation (47). Therein, 300 μCi (11.1) MBq 99Y impressively reduced growth of established tumors, but already 196 μCi (7.2 MBq) 99Y resulted in functional renal damages manifested by high serum creatinine concentration.

The single administration of 29.6 MBq 177Lu ABD-(ZHER2:342)2 resulted in overall mortality within 18 days due to bone marrow toxicity. Albumin-binding affinity, although effective in reducing renal toxicity, increased the exposure to bone and bone marrow. However, a potential advantage of the use of reversible binding to albumin is that it opens for the possibility of fine tuning the drug pharmacokinetics by modifying its affinity to albumin (34). For example, to improve the therapeutic safety window, albumin-binding affinity may be decreased to reduce exposure to bone marrow, while increasing renal exposure within the region of safety.

Conceivably, such an approach could be used not only for targeted radionuclide therapy but also in other occasions where tailoring of the blood plasma half-life of a drug is desired. Taken together, our results show that fusion with ABD may improve the in vivo biodistribution of small tumor-targeting peptides intended for radiotherapy. This modification renders 177Lu-CHX-Aβ5-DTPA-ABD-(ZHER2:342)2 a promising candidate for treatment of micrometastases of HER2-expressing malignant tumors.

Acknowledgments

Received 3/5/2006; revised 10/25/2006; accepted 1/9/2007.

Support: We acknowledge Freds & Ingegerd Neumanns Foundation, Swedish Cancer Society and Swedish Governmental Agency for Innovation Systems (VINNOVA).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Veronika Eriksson, Lena Israelsson, Ylva Lindman, and the staff of the animal facility at Rudbeck Laboratory for technical assistance and Dr. Lars Abrahamsson (Affibody AB) for comments on the article.

References


Radionuclide Therapy of HER2-Positive Microxenografts Using a \(^{177}\)Lu-Labeled HER2-Specific Affibody Molecule

Vladimir Tolmachev, Anna Orlova, Rikard Pehrson, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/67/6/2773

Cited articles
This article cites 49 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/67/6/2773.full.html#ref-list-1

Citing articles
This article has been cited by 20 HighWire-hosted articles. Access the articles at:
/content/67/6/2773.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.